Abstracts tagged "risk factors"

Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0994 • ACR Convergence 2024
Association Between Cardiovascular Risk Factors and the Onset of Giant Cell Arteritis: A Systematic Review and Meta-analysis
François Barde¹, Lucas Pacoureau², Alexis Elbaz², Raphaele Seror³ and Yann Nguyen⁴, ¹Inserm, CESP, Paris, France, ²Inserm, CESP, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ⁴Université Paris Saclay, Clichy, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) predominantly affects people over 50 years of age, with a female predominance. Its pathophysiological mechanism is currently under debate. In…
Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Chunhui Chen¹, Emily Wu², Huong Do³ and Kyriakos Kirou³, ¹New York Presbyterian Queens, Flushing, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
Abstract Number: 2369 • ACR Convergence 2024
Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
Philip Mease¹, Laura Coates², Alexis Ogdie³, Dafna Gladman⁴, Alen Zabotti⁵, Xenofon Baraliakos⁶, Cynthia Deignan⁷, Shauna Jardon⁷, Rebecca Wang⁷, Lichen Teng⁷ and Laure Gossec⁸, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Udine, Italy, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Sorbonne Université, Paris, France
Background/Purpose: In the FOREMOST study of early oligoarticular psoriatic arthritis (PsA), fewer patients (pts) receiving apremilast (APR) progressed from ≤4 active joints (all joints; oligoarthritis)…
Abstract Number: 0049 • ACR Convergence 2024
Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Alexandra Circiumaru², Denis Lagutkin¹, Masa Filipovic¹, Anca Catrina¹, Caroline Grönwall¹, Aase Hensvold¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden
Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…
Abstract Number: 0627 • ACR Convergence 2024
Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease
Matthew Chung¹, John Shelley², John Still², Gul Karakoc³, Xiaodi Ruan⁴, Jonathan D. Mosley⁴, C. Michael Stein⁴ and Vivian K. Kawai⁴, ¹VU, Nashville, TN, ²VUMC, Nashville, TN, ³Vanderbilt University Medical Center, Mt. Pleasant, SC, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that are commonly present in SLE and other autoimmune (AI) disorders. However, a positive ANA…
Abstract Number: 1001 • ACR Convergence 2024
Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis
Virginia Pascual Ramos¹, Guillermo Guaracha Basañez², Irazú Contreras-Yáñez³, Loraine Ledón-LLanes⁴, Ana Ortiz-Haro⁴ and Guillermo A Guaracha-Basañez⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico city, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico
Background/Purpose: Mistreatment is a complex problem that impacts people's quality of life, morbidity, and mortality. In aged people, it has been associated with female sex,…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 2414 • ACR Convergence 2024
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Alma Aveytia Camacho¹, Rakesh Gullapelli², Vineetha Philip³, Soudabeh Daliri¹, Ruba Memon⁴, Helene DiGregorio², Lily Romero Karam², Kanika Monga³, Eleonora Avenatti², Khurram Nasir² and Myriam Guevara¹, ¹Houston Methodist, Houston, TX, ²Houston Methodist Hospital, Houston, TX, ³Houston Methodist Hospital, Sugar Land, TX, ⁴Houston Methodist, Missouri City, TX
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…
Abstract Number: 0056 • ACR Convergence 2024
Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Ryo Motoyama¹, Shohei Nakamura¹, Eisuke Inoue², Hideto Takada³, Masayoshi Harigai⁴ and Yuko okamoto¹, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University, Denver, CO, ⁴International University of Health and Welfare, Tokyo, Japan
Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…
Abstract Number: 0660 • ACR Convergence 2024
Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis
Shivani Garg¹, Brad Rovin², Brad Astor¹, Tripti Singh¹, Lexie Kolton¹, Callie Saric¹, S. Sam Lim³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²The Ohio State University, Columbus, OH, ³Emory University, Atlanta, GA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
Abstract Number: 1003 • ACR Convergence 2024
Association Between Metabolic Markers and Knee Osteoarthritis: A Cross-sectional Study Using the Korea National Health and Nutrition Examination Survey 2009 to 2013
Junyong Park, Minkook Son, Sang Yeob Lee, Won Tae Chung and Sung Won Lee, Dong-A University College of Medicine, Busan, Republic of Korea
Background/Purpose: Low-grade, prolonged inflammation of involved joint is characteristic of osteoarthritis (OA) pathogenesis. Thus susceptibility to inflammation has been considered as a risk factor for…
Abstract Number: 1613 • ACR Convergence 2024
Adherence to Dietary Recommendations and the Risk of Developing Giant Cell Arteritis; A Nested Case-Control Study
Poi Kwanyuen¹, Karin Wadström¹, Emily Sonestedt¹, Charlotta Fors¹, Rebecka Bäcklund¹, Aladdin Mohammad², Lennart TH Jacobsson¹ and Carl Turesson¹, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: Giant cell arteritis (GCA) affects large and medium-sized vessels in elderly individuals. Previous studies have reported associations with lower body mass index and lower…
Abstract Number: 2429 • ACR Convergence 2024
Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
Carmen Raya-Santos¹, José Rosas-Gómez de Salazar², Mariana Marco³, Ana Pons-Bas³, Rocío Gallego Campuzano⁴, Juan Carlos Cortes⁴, Lara Pons-Canet³, Maruan Shalabi³, José Miguel Senabre³, José Antonio Bernal⁵, Gregorio Santos-Soler⁶, Xavier Barber⁷ and Jose Alberto Garcia Gomez⁷, ¹Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ³Hospital Marina Baixa, Villajoyosa, Spain, ⁴Hospital Marina Baixa, Villajoyosa, Comunidad Valenciana, Spain, ⁵Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ⁶Hospital Marina Baixa, Villajoyosa, ⁷Miguel Hernandez University, Villajoyosa, Spain
Background/Purpose: The administration of hydroxychloroquine-sulphate (HCQ) can lead to the risk of QTc prolongation and cardiac arrhythmias. We evaluated the HCQ concentration and the incidence…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].